Literature DB >> 2516176

Neurological deterioration in adult phenylketonuria.

D Villasana1, I J Butler, J C Williams, S M Roongta.   

Abstract

A 28-year-old man with classical phenylketonuria had increased seizure frequency and rapidly progressive spasticity. There was a marked reduction of biogenic amine neurotransmitter metabolites in cerebrospinal fluid. Dietary therapy reduced serum phenylalanine levels, improved symptoms of hypertonicity, and cerebrospinal fluid neurotransmitter metabolites became normal. An adolescent male with classical phenylketonuria, treated by dietary restriction until age 6 years, was assessed for decreasing school performance at 18 years. Cerebrospinal fluid biogenic amine neurotransmitter metabolites were significantly reduced. Magnetic resonance imaging in both subjects showed multiple areas of increased signal intensity in cerebral white matter. Neuropathological changes in classical phenylketonuria have been characterized as a dysmyelinating or demyelinating process. Neurochemical studies show a defect in brain lipids and biogenic amine metabolism. In the past, dietary therapy was directed at reducing hyperphenylalaninaemia only during the first decade of life. This report, as well as other studies, indicates that dietary therapy should be lifelong in patients with classical phenylketonuria, in order to prevent progressive and insidious neurological deterioration in later life.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516176     DOI: 10.1007/bf01802042

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  A chemical investigation of the defects of myelination in phenylketonuria.

Authors:  L CROME; V TYMMS; L I WOOLF
Journal:  J Neurol Neurosurg Psychiatry       Date:  1962-05       Impact factor: 10.154

2.  Neuro-pathologic observations in phenylketonuria.

Authors:  C M POSER; L VAN BOGAERT
Journal:  Brain       Date:  1959-03       Impact factor: 13.501

3.  Neuropathological findings in phenyl-pyruvic oligophrenia (phenyl-ketonuria).

Authors:  E C ALVORD; L D STEVENSON; F S VOGEL; R L ENGLE
Journal:  J Neuropathol Exp Neurol       Date:  1950-07       Impact factor: 3.685

4.  Diet discontinuation in phenylketonuria.

Authors:  M Williamson; R Koch; S Berlow
Journal:  Pediatrics       Date:  1979-05       Impact factor: 7.124

5.  The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain.

Authors:  C M McKean
Journal:  Brain Res       Date:  1972-12-12       Impact factor: 3.252

6.  Neuropathology of phenylketonuria.

Authors:  N Malamud
Journal:  J Neuropathol Exp Neurol       Date:  1966-04       Impact factor: 3.685

7.  Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia.

Authors:  I J Butler; M E O'Flynn; W E Seifert; R R Howell
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

8.  Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid.

Authors:  W E Seifert; J L Foxx; I J Butler
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

9.  Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents.

Authors:  H C Lou; F Güttler; C Lykkelund; P Bruhn; A Niederwieser
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

10.  Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction.

Authors:  M R Seashore; E Friedman; R A Novelly; V Bapat
Journal:  Pediatrics       Date:  1985-02       Impact factor: 7.124

View more
  24 in total

1.  Neurological deterioration in adult phenylketonuria.

Authors:  J Weglage; C Oberwittler; T Marquardt; J Schellscheidt; A von Teeffelen-Heithoff; G Koch; H Gerding
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

2.  Decreasing choline signal--a marker of phenylketonuria?

Authors:  M Dezortová; L Hejcmanová; M Hájek
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

3.  Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging.

Authors:  U Bick; G Fahrendorf; A C Ludolph; P Vassallo; J Weglage; K Ullrich
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

4.  Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

5.  Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability.

Authors:  A C Ludolph; U Vetter; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

6.  Polyunsaturated fatty acid status in patients with phenylketonuria.

Authors:  P Sanjurjo; L Perteagudo; J Rodríguez Soriano; A Vilaseca; J Campistol
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

7.  Vitamin B12 deficiency in adolescents and young adults with phenylketonuria.

Authors:  W B Hanley; A S Feigenbaum; J T Clarke; W E Schoonheyt; V J Austin
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency.

Authors:  J Pietz; U K Meyding-Lamadé; H Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Care of the adult with phenylketonuria.

Authors:  R Koch; C Azen; E G Friedman; K Fishler; C Baumann-Frischling; T Lin
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Phenylketonuria: treatment in adolescence and adult life.

Authors:  D P Brenton; A C Tarn; J C Cabrera-Abreu; M Lilburn
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.